Department of Dermatology, University of Bonn Germany.
Ther Clin Risk Manag. 2007 Jun;3(3):411-20.
Alefacept is the first biological agent approved by the US Food and Drug Administration (FDA) for the treatment of moderate to severe chronic plaque psoriasis. It is a full human fusion protein binding to CD2 on T cells. With its dual mechanism of action, alefacept blocks the interaction between the leukocyte-function-associated antigen (LFA)-3 and CD2 and thereby impedes the activation and proliferation of T cells. In addition, alefacept induces apoptosis of activated memory T cells. This paper presents an overview about the clinical studies on alefacept, its mechanism of action, and the results of the clinical trials focused on efficacy and safety of alefacept in different populations. Further on, data available on the use of alefacept in combination with other therapeutic agents are discussed.
阿法赛普是美国食品药品监督管理局（FDA）批准的首个用于治疗中重度慢性斑块型银屑病的生物制剂。它是一种与人源细胞表面分子 CD2 特异性结合的全人源融合蛋白。其双重作用机制为：阻断白细胞功能相关抗原（LFA）-3 与 CD2 的相互作用，从而抑制 T 细胞的激活和增殖；诱导活化的记忆 T 细胞凋亡。本文就阿法赛普的临床研究、作用机制以及临床试验结果，包括不同人群中的疗效和安全性，进行综述。此外，还讨论了阿法赛普与其他治疗药物联合应用的数据。
